To Explore the Mechanism and Equivalent Molecular Group of Radix Astragali and Semen Lepidii in Treating Heart Failure Based on Network Pharmacology.

4区医学 Q2 Medicine

Evidence-based Complementary and Alternative Medicine Pub Date : 2021-07-03 eCollection Date: 2021-01-01 DOI:10.1155/2021/5518192

Yi-Ding Yu, Yi-Ping Xiu, Yang-Fan Li, Juan Zhang, Yi-Tao Xue, Yan Li

{"title":"To Explore the Mechanism and Equivalent Molecular Group of Radix Astragali and Semen Lepidii in Treating Heart Failure Based on Network Pharmacology.","authors":"Yi-Ding Yu, Yi-Ping Xiu, Yang-Fan Li, Juan Zhang, Yi-Tao Xue, Yan Li","doi":"10.1155/2021/5518192","DOIUrl":null,"url":null,"abstract":"<p><p>Radix Astragali and Semen Lepidii (HQ-TLZ) is a commonly used herbal medicine combination for treatment of heart failure, which has a good clinical effect. However, its active components and mechanism of action are not clear, which limits its clinical application and development. In this study, we explored the mechanism of action of HQ-TLZ in the treatment of heart failure based on network pharmacology. We obtained 11 active ingredients and 109 targets from the TCMSP database and SwissTargetPrediction database. Next, we constructed the action network and carried out enrichment analysis. The results showed that HQ-TLZ treatment of heart failure is primarily achieved by regulating the insulin resistance, erbB signaling pathway, PI3K-Akt signaling pathway, and VEGF signaling pathway. After inverse targeting, molecular docking, and literature search, we determined that the equivalent molecular groups of HQ-TLZ in the treatment of heart failure were quercetin and kaempferol. Based on network pharmacology, we reveal the mechanism of action of HQ-TLZ in the treatment of heart failure to a certain extent. At the same time, we determined the composition of the equivalent molecular group. This provides a bridge for the consistency evaluation of natural herbs and molecular compounds, which is beneficial to the development of novel drugs and further research.</p>","PeriodicalId":12236,"journal":{"name":"Evidence-based Complementary and Alternative Medicine","volume":" ","pages":"5518192"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275399/pdf/","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Complementary and Alternative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/5518192","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 3

Abstract

Radix Astragali and Semen Lepidii (HQ-TLZ) is a commonly used herbal medicine combination for treatment of heart failure, which has a good clinical effect. However, its active components and mechanism of action are not clear, which limits its clinical application and development. In this study, we explored the mechanism of action of HQ-TLZ in the treatment of heart failure based on network pharmacology. We obtained 11 active ingredients and 109 targets from the TCMSP database and SwissTargetPrediction database. Next, we constructed the action network and carried out enrichment analysis. The results showed that HQ-TLZ treatment of heart failure is primarily achieved by regulating the insulin resistance, erbB signaling pathway, PI3K-Akt signaling pathway, and VEGF signaling pathway. After inverse targeting, molecular docking, and literature search, we determined that the equivalent molecular groups of HQ-TLZ in the treatment of heart failure were quercetin and kaempferol. Based on network pharmacology, we reveal the mechanism of action of HQ-TLZ in the treatment of heart failure to a certain extent. At the same time, we determined the composition of the equivalent molecular group. This provides a bridge for the consistency evaluation of natural herbs and molecular compounds, which is beneficial to the development of novel drugs and further research.

Abstract Image

查看原文本刊更多论文

基于网络药理学探讨黄芪、蛇尾治疗心衰的作用机制及等效分子群。

黄芪和乐皮子（HQ-TLZ）是治疗心力衰竭的常用中草药组合，具有良好的临床疗效。然而，其活性成分和作用机制尚不清楚，这限制了其临床应用和发展。本研究以网络药理学为基础，探讨HQ-TLZ治疗心力衰竭的作用机制。我们从TCMSP数据库和SwissTargetPrediction数据库中获得了11种活性成分和109个靶标。接下来，我们构建了行动网络，并进行了丰富性分析。结果表明，HQ-TLZ治疗心力衰竭主要通过调节胰岛素抵抗、erbB信号通路、PI3K-Akt信号通路和VEGF信号通路来实现。经过反向靶向、分子对接和文献检索，我们确定HQ-TLZ治疗心力衰竭的等效分子基团为槲皮素和山奈酚。基于网络药理学，我们在一定程度上揭示了HQ-TLZ治疗心力衰竭的作用机制。同时，我们确定了等效分子基团的组成。这为天然草药和分子化合物的一致性评价提供了桥梁，有利于新药的开发和进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Evidence-based Complementary and Alternative Medicine 医学-全科医学与补充医学

自引率

0.00%

发文量

1983

审稿时长

2.2 months

期刊介绍： Evidence-Based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research in this new, yet ancient world of complementary and alternative medicine. The journal seeks to apply scientific rigor to the study of complementary and alternative medicine (CAM) modalities, particularly traditional Asian healing systems. eCAM emphasizes health outcome, while documenting biological mechanisms of action. The journal is devoted to the advancement of science in the field of basic research, clinical studies, methodology or scientific theory in diverse areas of Biomedical Sciences. The journal does not consider articles on homeopathy.